Ping Li, MD
Epilepsy · Buffalo, NYNPI 1619132651
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Livanova USA, Inc. at 30.5% of the total.
Across 155 payments — averaging $40.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Neuropace, Inc.$1K
- SK Life Science, Inc.$1K
- UCB, Inc.$760
- Medtronic$503
- Greenwich Biosciences, Inc.$194
- plus $557 from 11 others
Across 8 payments — averaging $5931.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$35K
- SK Life Science, Inc.$9K
- Medtronic$3K
What the payments were for
- Food & beverage$6,328100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 65 | $1,930 |
| Neuropace, Inc. | 18 | $1,225 |
| SK Life Science, Inc. | 18 | $1,159 |
| UCB, Inc. | 24 | $760 |
| Medtronic(2 entities) | 7 | $503 |
| Greenwich Biosciences, Inc. | 3 | $194 |
| Jazz Pharmaceuticals Inc. | 6 | $158 |
| Eisai Inc. | 1 | $125 |
| Neurelis, Inc. | 4 | $74 |
| Aucta Pharmaceuticals, Inc. | 1 | $30 |
| AbbVie | 1 | $30 |
| Biogen | 1 | $26 |
| Supernus Pharmaceuticals, Inc. | 2 | $25 |
| Boston Scientific | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Pfizer | 1 | $21 |
| Acorda Therapeutics, Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$468
- RNS Neurostimulator Kit$402
- XCOPRI$369
- ACTIVA$178
- PERCEPT PC BRAINSENSE$155
- Fycompa$125
- Fintepla$122
- Epidiolex$110
- RNS System$100
How this compares
$6,328 in reported general payments places this provider in the 65th percentile of 21 epilepsy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 51 | $331,981 |
| AptiomEslicarbazepine Acetate | 75 | $126,548 |
| LamictalLamotrigine | 42 | $57,605 |
| KeppraLevetiracetam | 29 | $53,723 |
| Oxtellar XrOxcarbazepine | 44 | $50,856 |
| XcopriCenobamate | 25 | $42,656 |
| Keppra XrLevetiracetam | 15 | $39,409 |
| NeurontinGabapentin | 11 | $29,474 |
| Lacosamide | 233 | $29,278 |
| FycompaPerampanel | 23 | $29,025 |
| Levetiracetam | 518 | $24,155 |
| BriviactBrivaracetam | 18 | $23,824 |
| NayzilamMidazolam | 22 | $20,922 |
| Lamotrigine ErLamotrigine | 73 | $18,682 |
| Oxcarbazepine | 154 | $14,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $25 | $50,85644 claims |
| UCB, Inc.Briviact, Nayzilam | $760 | $44,74640 claims |
| SK Life Science, Inc.Xcopri | $1,159 | $42,65625 claims |
| Eisai Inc.Fycompa | $125 | $29,02523 claims |
| PfizerDilantin | $21 | $3,66621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 21 epilepsy providers in New York.
Other epilepsy in Buffalo
- Robert GloverBuffalo$88K
- Alexus LudwigBuffalo$2K
- Patricia DuganNew York$97K
- Daniel FriedmanNew York$66K
- Sheryl HautBronx$61K
- Christopher ElderNew York$41K
- Benjamin BlondStony Brook$40K
- Andres Rodriguez-RuizBrooklyn$9K
- Mill EtienneSuffern$3K
- Susanna O'KulaBrooklyn$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.